Perceptive Advisors’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Perceptive Advisors’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-750,000	Closed	-$2.65M	–	113
2022 Q3	$2.65M	Buy	+750,000	New	+$2.48M	0.08%	96
2021 Q4	–	Sell	-787,745	Closed	-$5.74M	–	159
2021 Q3	$5.74M	Hold	787,745	–	–	0.08%	118
2021 Q2	$7.89M	Hold	787,745	–	–	0.1%	115
2021 Q1	$7.52M	Hold	787,745	–	–	0.1%	103
2020 Q4	$8.64M	Hold	787,745	–	–	0.09%	110
2020 Q3	$6.99M	Buy	+787,745	New	+$8.96M	0.1%	100

Other funds holding PSTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Perceptive Advisors's PSTX Position: Q4 2022 in Review

Perceptive Advisors sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2022, closing a stake of 750,000 shares — an estimated $2.65M sold.

Perceptive Advisors first reported a position in PSTX in Q3 2020 and held it in 6 quarters. The position peaked at $8.64M in Q4 2020. 89 funds tracked by Wall St. Rank hold PSTX as of Q4 2022.

Perceptive Advisors reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Perceptive Advisors sold 750,000 Poseida Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $2.65M.
Perceptive Advisors first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 6 quarters.
Perceptive Advisors's Poseida Therapeutics, Inc. Common Stock position peaked at $8.64M in Q4 2020.
89 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Perceptive Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.